NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- According to a new research report published by Pharma Proff, a brand of P&S Intelligence, uveitis therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Uveitis refers to a group of disorders that lead to inflammation in eyes and damages their tissues. The disease not only affects uvea, which is the middle layer of the eye, but also affects retina, vitreous humor, optic nerve, and iris. In severe cases, uveitis may lead to partial or complete loss of vision. Some of the commonly occurring symptoms of the disease include blurred vision, floating spots in eye, redness, pain, diminished pupil, headache, and photophobia. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis, and pan-uveitis.

Request to get the sample pages of the report @ https://www.pharmaproff.com/request-sample/1229

The actual cause of the disease is unknown, however, diseases including juvenile arthritis, psoriasis, rheumatoid arthritis, Crohn’s disease, HIV/AIDS, herpes simplex infection, and lyme disease increase the risk of developing uveitis. The occurrence of uveitis can be diagnosed by a physical examination, blood test, skin test, examination of eye fluid, X-ray, or tests including split lamp, visual acuity, fundoscopic exam, and ocular pressure.

Humira (AbbVie Inc.), Kenalog-40 (Bristol-Myers Squibb Company), Ozudrex (Allergan Inc.) and Durezol (Novartis International AG) are some of the drugs approved by the U.S. Food and Drug Administration (USFDA) for the treatment of uveitis.

Browse Detailed Report at:https://www.pharmaproff.com/report/uveitis-therapeutics-pipeline-analysis

According to the research findings, majority of pipeline drug candidates are being developed for topical administration. It has been observed that this route possesses reproducible effects. Moreover, drugs administered by this route are less invasive as compared to other routes of administration.

Companies that are involved in developing therapeutics for uveitis have shown positive clinical results in various phases of drug development. For instance, in September 2018, Santen Pharmaceutical Co. Ltd. announced positive data of phase III trial of opsiria for the treatment of patients with uveitis. The results of the study concluded that treatment with opsiria has a favorable safety and tolerability profile. The study also recorded efficacy of opsiria in lowering down the inflammation in the eye.

Humira of AbbVie Inc. was granted Orphan Drug Designation for the treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis in 2014 and the drug was approved for marketing in 2018. Therefore, with the emergence of late- and mid-stage pipeline products in the market, the overall uveitis therapeutics market is expected to grow significantly in the upcoming years.

Make enquiry before purchasing the report @ https://www.pharmaproff.com/enquiry/1229

Panoptes Pharma Ges.m.b.H, Gilead Sciences Inc., Santen Pharmaceutical Co. Ltd., Aldeyra Therapeutics Inc., Novartis International AG, Bristol-Myers Squibb Company, AbbVie Inc., Allergan Inc., Bausch Health Companies Inc., Galapagos NV, NovelMed Inc., Mitotech, and Clearside Biomedical Inc. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of uveitis.

Uveitis Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Other Publication by Pharma Proff

Presbyopia Therapeutics

Graves’ Ophthalmopathy Therapeutics

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of uveitis. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the uveitis therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to uveitis.

About Pharma Proff

Pharma Proff, a brand of P&S Intelligence, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:

Pharma Proff

Toll-free: +1-888-778-7886 (USA/Canada)

International: +1-347-960-6455

Email: enquiry@pharmaproff.com

Web: https://www.pharmaproff.com

Connect with us: LinkedIn | Twitter | Facebook